Should I buy or sell Pulmatrix stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PULM shares. View PULM analyst ratings or view top-rated stocks .

What is Pulmatrix's stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for PULM or view top-rated stocks among Wall Street analysts .

How have PULM shares performed in 2023?

Pulmatrix's stock was trading at $3.88 at the beginning of 2023. Since then, PULM stock has decreased by 48.5% and is now trading at $2.00. View the best growth stocks for 2023 here .

Are investors shorting Pulmatrix?

Pulmatrix saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,100 shares, a decrease of 38.2% from the October 31st total of 3,400 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short. View Pulmatrix's Short Interest .

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our PULM earnings forecast .

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) EPS for the quarter, missing analysts' consensus estimates of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 64.09% and a negative net margin of 238.89%.

When did Pulmatrix's stock split?

Pulmatrix's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Acasti Pharma (ACST) , Biocept (BIOC) , Heat Biologics (HTBX) , Trevena (TRVN) , TherapeuticsMD (TXMD) , Verastem (VSTM) and Evoke Pharma (EVOK) .

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (4.15%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Pulmatrix Stock Price, News & Analysis (NASDAQ:PULM)

$2.00

+0.06 (+3.09%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.96
▼
$2.06
50-Day Range: $1.74
▼
$2.20
52-Week Range: $1.64
▼
$4.49

Volume: 19,704 shs
Average Volume: 19,926 shs
Market Capitalization: $7.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Pulmatrix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$10.00 Price Target
Short Interest: Healthy
0.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($4.34) to ($4.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Pulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Pulmatrix has a forecasted upside of 400.0% from its current price of $2.00.
Amount of Analyst Coverage
Pulmatrix has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.06% of the float of Pulmatrix has been sold short.
Short Interest Ratio / Days to Cover
Pulmatrix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pulmatrix has recently decreased by 38.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pulmatrix does not currently pay a dividend.
Dividend Growth
Pulmatrix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PULM.

2.8

News and Social Media Coverage

News Sentiment
Pulmatrix has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Pulmatrix this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for PULM on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pulmatrix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.61% of the stock of Pulmatrix is held by insiders.
Percentage Held by Institutions
Only 11.62% of the stock of Pulmatrix is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pulmatrix are expected to decrease in the coming year, from ($4.34) to ($4.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pulmatrix is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pulmatrix is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pulmatrix has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pulmatrix Stock (NASDAQ:PULM)

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

PULM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PULM Stock News Headlines

November 24, 2023 | americanbankingnews.com

Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

November 12, 2023 | morningstar.com

Pulmatrix Inc PULM

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 9, 2023 | baystreet.ca

Pulmatrix Down on Q3 Results

November 9, 2023 | msn.com

Pulmatrix GAAP EPS of -$1.03, revenue of $1.75M

November 9, 2023 | finance.yahoo.com

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

October 23, 2023 | finance.yahoo.com

Aspergillosis Treatment Research Report 2023

September 19, 2023 | markets.businessinsider.com

Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

September 19, 2023 | finance.yahoo.com

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

September 11, 2023 | msn.com

Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 23, 2023 | finance.yahoo.com

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

August 10, 2023 | finanznachrichten.de

Pulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 10, 2023 | msn.com

Pulmatrix GAAP EPS of -$1.04, revenue of $1.84M

August 10, 2023 | finance.yahoo.com

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 11, 2023 | finance.yahoo.com

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

June 15, 2023 | finance.yahoo.com

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023 | finance.yahoo.com

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Pulmatrix (PULM)

May 12, 2023 | msn.com

Pulmatrix GAAP EPS of -$1.22, revenue of $1.5M

May 12, 2023 | finance.yahoo.com

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023 | marketwatch.com

Injectable Drug Delivery Technology Market: Latest Innovations, Drivers and Industry Key Events 2023-2031

May 2, 2023 | finance.yahoo.com

Pulmatrix Supports World Asthma Day 2023

April 20, 2023 | sg.finance.yahoo.com

Pulmatrix, Inc. (PULM) stock historical prices & data – Yahoo Finance

March 30, 2023 | finance.yahoo.com

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

February 27, 2023 | marketwatch.com

Injectable Drug Delivery Devices Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028

February 18, 2023 | marketwatch.com

Global Targeted Drug Delivery System Market 2023 Global Share, Key Country Analysis and Forecasts 2030 By VMReports

See More Headlines

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/29/2022
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PULM
CUSIP: N/A
CIK: 1574235
Web: www.pulmatrix.com
Phone: (781) 357-2333
Fax: 707-525-9906
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +411.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,840,000.00
Net Margins: -238.89%
Pretax Margin: -238.89%
Return on Equity: -64.09%
Return on Assets: -44.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.24
Quick Ratio: 5.24

Sales & Book Value

Annual Sales: $6.07 million
Price / Sales: 1.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.55 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 3,650,000
Free Float: 3,520,000
Market Cap: $7.14 million
Optionable: Not Optionable
Beta: 0.82

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Teofilo David Raad MBA (Age 53)
President, CEO & Director
Comp: $772.7k
Mr. Peter Ludlum CMA (Age 68)
MBA, Interim CFO and Principal Accounting & Financial Officer
Comp: $398.58k
Dr. Margaret M. Wasilewski M.D. (Age 66)
Chief Medical Officer
Comp: $585.84k
Dr. Alexander M. Klibanov Ph.D. (Age 73)
Founder

Key Competitors

View All Competitors

Institutional Ownership

Sabby Management LLC
Sold 32,724 shares on 11/15/2023
Ownership: 4.147%

View All Institutional Transactions

PULM Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings or view top-rated stocks.
What is Pulmatrix's stock price target for 2024?: 1 Wall Street research analysts have issued 12-month price objectives for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for PULM or view top-rated stocks among Wall Street analysts.
How have PULM shares performed in 2023?: Pulmatrix's stock was trading at $3.88 at the beginning of 2023. Since then, PULM stock has decreased by 48.5% and is now trading at $2.00.
View the best growth stocks for 2023 here.
Are investors shorting Pulmatrix?: Pulmatrix saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,100 shares, a decrease of 38.2% from the October 31st total of 3,400 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.
View Pulmatrix's Short Interest.
When is Pulmatrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our PULM earnings forecast.
How were Pulmatrix's earnings last quarter?: Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) EPS for the quarter, missing analysts' consensus estimates of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 64.09% and a negative net margin of 238.89%.

When did Pulmatrix's stock split?: Pulmatrix's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Pulmatrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).
Who are Pulmatrix's major shareholders?: Pulmatrix's stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (4.15%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Pulmatrix?: Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PULM) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial